INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
01/30/2026
Back to search
Official data from USPTO
MEDSIR MEDICA SCIENTIA INNOVATION RESEARCH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
39
Latest update
01/31/2026
Trademark type
Combined
Nice classes
42
Filing date
11/03/2017
Registration date
11/13/2018
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/30/2025
Last transaction
01/31/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
3
Owner type
99
Owner location
ES
Examiner
VAGHANI, MAYUR C
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized word "MED SIR" with "MED" in black and "SIR" in orange, the letter "S" has a double helix design in the background in light orange; below is the wording "MEDICA SCIENTIA" in orange and "INNOVATION RESEARCH" in black. The colors white represents background, outlining, shading, and/or transparent areas and is not part of the mark.
Holders and representatives
Holders
MEDICA SCIENTIA INNOVATION RESEARCH, S.L.
M. C. (pessoa física)
Representatives
Jason L DeFrancesco Hill Wallack LLP
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Scientific and technological servicesscientific research in the field of oncology; medical and pharmacological research services; consultancy relating to laboratory testing; consultancy relating to research and development in the field of therapeutics; consultancy relating to pharmacology; consultancy relating to pharmaceutical research and development; development of pharmaceutical preparations and medicines; clinical trials for others for test studiescontrol groupsparticipants with cancer; evaluation of pharmaceutical products; scientific and medical information regarding pharmaceutical products and clinical trials; biological researchclinical and medical research in the field of oncology; scientific research with a medical purpose; medical research; scientific research and development; pharmaceutical drug development services; biomedical research services; pharmaceutical research services; laboratory research services relating to pharmaceutical products; medical research laboratory services; medical laboratory services; provision of information regarding results of clinical trials relating to pharmaceutical products
Publications
History of USPTO decisions and trademark events.
39 publications found
C71T
CANCELLED SECTION 71
05/30/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
11/13/2023
CHLD
CHANGE OF OWNER RECEIVED FROM IB
07/30/2021
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
12/10/2020
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
11/01/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/30/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/11/2020
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/09/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/09/2019
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/16/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/26/2019
FIMP
FINAL DISPOSITION PROCESSED
02/26/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/13/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
11/13/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/28/2018
PUBO
PUBLISHED FOR OPPOSITION
08/28/2018
GPNX
NOTIFICATION PROCESSED BY IB
08/24/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/08/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/08/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
08/08/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
07/20/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
07/20/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/20/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
07/20/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/20/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/02/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/02/2018
ALIE
ASSIGNED TO LIE
06/26/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/12/2018
RFNT
REFUSAL PROCESSED BY IB
04/07/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/21/2018
RFRR
REFUSAL PROCESSED BY MPU
03/21/2018
MAFR
APPLICATION FILING RECEIPT MAILED
03/16/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/15/2018
CNRT
NON-FINAL ACTION WRITTEN
03/14/2018
DOCK
ASSIGNED TO EXAMINER
03/12/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/12/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/08/2018
Continuous trademark protection
Get notified about every new filing that threatens MEDSIR MEDICA SCIENTIA INNOVATION RESEARCH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.